Trials in kidney disease - Time to EVOLVE

New England Journal of Medicine

Volumn 367, Issue 26, 2012, Pages 2541-2542

  Perkovic, Vlado ^a   Neal, Bruce ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CINACALCET; PLACEBO;

CALCINOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALIGNANT NEOPLASTIC DISEASE; PARATHYROIDECTOMY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME;

EID: 84871673877     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1212368     Document Type: Editorial

References (8)

1. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with allcause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81.
2. U.S. Renal Data System. USRDS 2012 annual data report. Bethesda, MD: National Institutes of Health, 2012.
3. Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011;305:1119-27.
4. Strippoli GF, Palmer S, Tong A, Elder G, Messa P, Craig JC. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 2006;47:715-26.
5. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess 2007;11:iii, xi-xiii, 1-167.
6. The EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367:2482-94.
7. Joffe HV, Parks MH, Temple R. Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus. Rev Endocr Metab Disord 2010;11:21-30.
8. Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: Food and Drug Administration, 2008.